Torii Pharmaceutical Co (TSE:4551) 3-Year EPS without NRI Growth Rate : -1.70% (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co 3-Year EPS without NRI Growth Rate?

Torii Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2024 was 円37.93.

During the past 12 months, Torii Pharmaceutical Co's average EPS without NRI Growth Rate was 95.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was -1.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 16.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Torii Pharmaceutical Co was 46.70% per year. The lowest was -42.40% per year. And the median was -2.50% per year.

Competitive Comparison of Torii Pharmaceutical Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Torii Pharmaceutical Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Torii Pharmaceutical Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torii Pharmaceutical Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Torii Pharmaceutical Co's 3-Year EPS without NRI Growth Rate falls into.

Torii Pharmaceutical Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Torii Pharmaceutical Co (TSE:4551) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Torii Pharmaceutical Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Torii Pharmaceutical Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Torii Pharmaceutical Co (TSE:4551) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439

Website

http://www.torii.co.jp

Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines